1
Clinical Trials associated with recwt1-A10 adjuvant with AS01BEtude Phase I/II d'immunothérapie Par protéine recWT1-A10+AS01B après Greffe allogénique de Cellules Souches
Patients with acute or chronic myeloid leukemia, or myelodysplastic syndrome, underwent allogeneic stem cell transplantation from HLA-identical donor (related or unrelated) after reduced-intensity conditioning regimen.
If WT1 expression is detectable on tumor cells, they will receive an immune therapy 60 days after allograft.
6 administrations every 2 weeks of the protein recwt1-A10+AS01B will be administrated.
The safety and immunological efficacy of this immune therapy after hematopoietic stem cells transplantation with reduced intensity conditioning will be evaluated.
100 Clinical Results associated with recwt1-A10 adjuvant with AS01B
100 Translational Medicine associated with recwt1-A10 adjuvant with AS01B
100 Patents (Medical) associated with recwt1-A10 adjuvant with AS01B
100 Deals associated with recwt1-A10 adjuvant with AS01B